Mark J. Ratain to Melanoma
This is a "connection" page, showing publications Mark J. Ratain has written about Melanoma.
Connection Strength
1.217
-
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter. Clin Cancer Res. 2020 05 15; 26(10):2435.
Score: 0.547
-
Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7.
Score: 0.358
-
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 04; 95(5):581-6.
Score: 0.210
-
Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
Score: 0.049
-
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
Score: 0.035
-
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
Score: 0.019